This article was originally published in FierceHealthcare. While it has been over a month since the FDA announced its controversial decision to approve Biogen’s Alzheimer’s drug, Aduhelm, payers have been slow to make any decisions—and for good reason. While the excitement around the approval is undeniable given the long-overdue unmet